Skip to main content

Table 2 Comparison of antitumour efficacy of single and combined mAbs in the intraperitoneal tumour model

From: Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia

Injected mAbs

Medium survival in days

N° of tumour free animal at day 120 (%)

Anti-HLA-DR

> 120*

11/18

(61%)

Anti-CD5

81*

9/21

(43%)

Anti-CD71

56*

4/18

(22%)

Anti-HLA-DR + anti-CD5

> 120**

13/13

(100%)

Anti-CD71 +anti-CD5

> 120**

7/8

(88%)

Anti-CD71 + anti-HLA-DR

> 120

7/13

(54%)

Untreated animals

32

1/47

(2%)

  1. *significantly different from irrelevant IgG injected control mice (p < 0.005)
  2. **significantly different from both single antibody treatments (p < 0.05)
Back to article page

Molecular Cancer

ISSN: 1476-4598